Vanguard Global Advisers
LSTA icon

Vanguard Global Advisers’s Lisata Therapeutics LSTA Stock Holding History

Vanguard Global Advisers’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51K Hold
1,033
– – ﹤0.01% 3580
2026
Q1 		$5.17K Buy
+1,033
New +$4.26K ﹤0.01% 3554

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.14% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

Vanguard Global Advisers's LSTA Position: Q2 2026 in Review

Vanguard Global Advisers held its Lisata Therapeutics (LSTA) position steady in Q2 2026 at 1,033 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3580.

Vanguard Global Advisers first reported a position in LSTA in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.17K in Q1 2026. 30 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • Vanguard Global Advisers held 1,033 shares of Lisata Therapeutics worth $3.51K as of Q2 2026.
  • Vanguard Global Advisers left its Lisata Therapeutics share count unchanged in Q2 2026.
  • Lisata Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3580 holding.
  • Vanguard Global Advisers first reported a position in Lisata Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lisata Therapeutics position peaked at $5.17K in Q1 2026.
  • 30 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.